Rockefeller Capital Management’s Cognition Therapeutics CGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CGTX
C
CM
Rockefeller Capital Management's CGTX Position: Q3 2026 in Review
Rockefeller Capital Management held its Cognition Therapeutics (CGTX) position steady in Q3 2026 at 19,231 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3921.
Rockefeller Capital Management first reported a position in CGTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $26K in Q4 2025. 78 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.
- Rockefeller Capital Management held 19,231 shares of Cognition Therapeutics worth $18.5K as of Q3 2026.
- Rockefeller Capital Management left its Cognition Therapeutics share count unchanged in Q3 2026.
- Cognition Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3921 holding.
- Rockefeller Capital Management first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Rockefeller Capital Management's Cognition Therapeutics position peaked at $26K in Q4 2025.
- 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.